HDT Bio is a biopharmaceutical company having a far more extensive federal involvement than just SBIR. The firm is structured around providing immunotherapies for worldwide application to include those in historically underserved areas. Seeking to harness the bodys immune system to deliver therapies that narrowly target the specific areas of the body where they are needed, HDT Bios work focuses on oncological and infectious disease applications. The firm's founders and leadership are world renowned for their work in the arena of development of immune stimulants, including both therapeutics and therapy-enhancing adjuvants. One of the companys core technologies, RNA/LION, combines formulation and adjuvant ingredients to stabilize and deliver RNA to the immune system to stimulate responses for therapy or vaccination
